Gilead Sciences
GILD

$78.72

0.32%

Market Cap: $98.1B

About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Employees: 18,000

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

40% more call options, than puts

Call options by funds: $1.02B | Put options by funds: $726M

0% more funds holding in top 10

Funds holding in top 10: 13 [Q1] → 13 (+0) [Q2]

0.41% less ownership

Funds ownership: 83.52% [Q1] → 83.12% (-0.41%) [Q2]

6% less repeat investments, than reductions

Existing positions increased: 626 | Existing positions reduced: 669

3% less funds holding

Funds holding: 1,676 [Q1] → 1,628 (-48) [Q2]

6% less capital invested

Capital invested by funds: $76.2B [Q1] → $71.6B (-$4.56B) [Q2]

27% less first-time investments, than exits

New positions opened: 130 | Existing positions closed: 178

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$70

11%

downside

Avg. target

$78

2%

downside

High target

$93

18%

upside

10 analyst ratings

2 positive

20%

8 neutral

80%

0 negative

0%

RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target	6%downside $74	Sector Perform Maintained	4 Sept 2024
Truist Securities Robyn Karnauskas 43% 1-year accuracy 20 / 47 met price target	5%upside $83	Hold Maintained	15 Aug 2024
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target	9%downside $72	Sector Perform Maintained	9 Aug 2024
Cantor Fitzgerald Olivia Brayer 77% 1-year accuracy 20 / 26 met price target	11%downside $70	Neutral Reiterated	9 Aug 2024
BMO Capital Evan Seigerman 69% 1-year accuracy 9 / 13 met price target	8%upside $85	Outperform Maintained	9 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 24 articles about GILD published over the past 30 days

Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +

The 'Undercovered' Dozen series highlights 12 lesser-known stocks, offering fresh investment ideas and encouraging community discussion on their potential. Gen Alpha argues that EPR Properties, a diversified experiential REIT, shows promising tenant rent coverage and stability, especially with AMC's debt refinancing. Gilead Sciences' strong Q2 2024 results, robust HIV franchise, and high dividend yield support a continued "Buy" from ALLKA Research.

Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +

Gilead Sciences, Inc. (GILD) Wells Fargo 2024 Healthcare Conference (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo 2024 Healthcare Conference September 4, 2024 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Good morning, my name is Mohit Bansal. I'm one of the biopharma analyst here at Wells Fargo.

Gilead Sciences, Inc. (GILD) Wells Fargo 2024 Healthcare Conference (Transcript)

Gilead Sciences, Inc. (GILD) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley.

Gilead Sciences, Inc. (GILD) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company's broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presentations include: initial results from two cohorts of the EVOKE-02 study of Trodelvy® (sacituzumab govitecan-hziy).

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street

Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.

Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street

Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics to evaluate AVZO-021, a potential best-in-class CDK2 inhibitor, in combination with Trodelvy®, Gilead's Trop-2 directed ADC.

Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer

Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices

Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences will also be a player in the anti-obesity market. The stock is still trading for a reasonable valuation multiple and in case of a potential recession, pharmaceutical companies are often a good, recession-resilient pick.

Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Gilead Sciences: Buy This Bargain Before It's Gone

Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the company's HIV franchise amounted to about $4.75 billion in the second quarter, an increase of 9.3% quarter-on-quarter. In addition, on August 14, 2024, the FDA approved Livdelzi in combination with UDCA for the treatment of primary biliary cholangitis.

Gilead Sciences: Buy This Bargain Before It's Gone

Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi

Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset. Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset.

Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi

See News Rankings